Clarithromycin, montelukast, and pentoxifylline combination treatment ameliorates experimental neonatal hyperoxic lung injury

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 21, Issue 6, 2008, Pages 407-413

  Demir, Korcan ^a   Kumral, Abdullah ^a   Duman, Nuray ^a   Sarioglu, Sulen ^a   Yilmaz, Osman ^a   Yesilirmak, Didem Cemile ^a   Kargi, Aydanur ^a   Ozkan, Hasan ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Bronchopulmonary dysplasia; Clarithromycin; Hyperoxic lung injury; Montelukast; Newborn; Pentoxifylline

Indexed keywords

CLARITHROMYCIN; MONTELUKAST; PENTOXIFYLLINE; PLACEBO; SMOOTH MUSCLE ACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; HYPEROXIA; LUNG ALVEOLUS; LUNG DYSPLASIA; LUNG FIBROSIS; LUNG INJURY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; THORACOTOMY;

ACETATES; ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHOPULMONARY DYSPLASIA; CLARITHROMYCIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; INFANT, NEWBORN; LEUKOTRIENE ANTAGONISTS; OXYGEN INHALATION THERAPY; PENTOXIFYLLINE; QUINOLINES; RATS;

EID: 47349091412     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050802045715     Document Type: Article

References (36)

1. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet 2006;367:1421-1431.
2. D'Angio CT, Maniscalco WM. Bronchopulmonary dysplasia in preterm infants. Paediatr Drugs 2004;6:303-330.
3. Sweet DG, Halliday HL. A risk-benefit assessment of drugs used for neonatal chronic lung disease. Drug Saf 2000;22:389-404.
4. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723-1729.
5. Rubin BK. Immunomodulatory properties of macrolides: Overview and historical perspective. Am J Med 2004;117:2S-3S.
6. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004;117:5S-11S.
7. Reato G, Cuffini AM, Tullio V, Mandras N, Roana J, Banche G, Foa R, Carlone NA. Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophils. Int J Antimicrob Agents 2004;23:150-154.
8. Lyon AJ, McColm J, Middlemist L, Fergusson S, McIntosh N, Ross PW. Randomised trial of erythromycin on the development of chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998;78:F10-F14.
9. Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999;353:57-62.
10. Hosford GE, Koyanagi KS, Leung WI, Olson DM. Hyperoxia increases protein mass of 5-lipoxygenase and its activating protein, FLAP, and leukotriene B4 output in newborn rat lungs. Exp Lung Res 2002;28:671-684.
11. Jouvencel P, Fayon M, Choukroun ML, Carles D, Montaudon D, Dumas E, Begueret H, Marthan R. Montelukast does not protect against hyperoxia-induced inhibition of alveolarization in newborn rats. Pediatr Pulmonol 2003;35:446-451.
12. Haque K, Mohan P. Pentoxifylline for neonatal sepsis. Cochrane Database Syst Rev 2003;4:CD004205.
13. Krakauer T. Pentoxifylline inhibits ICAM-1 expression and chemokine production induced by proinflammatory cytokines in human pulmonary epithelial cells. Immunopharmacology 2000;46:253-261.
14. Michetti C, Coimbra R, Hoyt DB, Loomis W, Junger W, Wolf P. Pentoxifylline reduces acute lung injury in chronic endotoxinemia. J Surg Res 2003;115:92-99.
15. Naureckas ET, Factor P, Benjaminov O, Hoffer E, Sriram V, Sznajder JI. Pentoxifylline does not protect against hyperoxic lung injury in rats. Eur Respir J 1994;7:1397-1402.
16. ter Horst SA, Wagenaar GT, de Boer E, van Gastelen MA, Meijers JC, Biemond BJ, Walther FJ. Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. J Appl Physiol 2004;97:2014-2019.
17. Lauterbach R, Szymura-Oleksiak J. Nebulized pentoxifylline in successful treatment of five premature neonates with bronchopulmonary dysplasia. Eur J Pediatr 1999;158:607-610.
18. Ozer EA, Kumral A, Ozer E, Duman N, Yilmaz O, Ozkal S, Ozkan H. Effect of retinoic acid on oxygen-induced lung injury in the newborn rat. Pediatr Pulmonol 2005;39:35-40.
19. Zaher TE, Miller EJ, Morrow DM, Javdan M, Mantell LL. Hyperoxia-induced signal transduction pathways in pulmonary epithelial cells. Free Radic Biol Med 2007;42:897-908.
20. Kunig AM, Balasubramaniam V, Markham NE, Morgan D, Montgomery G, Grover TR, Abman SH. Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats. Am J Physiol Lung Cell Mol Physiol 2005;289:L529-L535.
21. Thadepalli H, Chuah SK, Iskandar L, Gollapudi S. Comparison of telithromycin, a new ketolide, with erythromycin and clarithromycin for the treatment of Haemophilus influenzae pneumonia in suckling, middle aged and senescent mice. Int J Antimicrob Agents 2002;20:180-185.
22. Stocker JT. Pathologic features of long-standing 'healed' bronchopulmonary dysplasia: A study of 28 3- to 40-month-old infants. Hum Pathol 1986;17:943-961.
23. Sarioglu S, Celik A, Sakar M, Sonmez D, Tekis D. Methenamine silver staining quantitative digital histochemistry in chronic allograft nephropathy. Transplant Proc 2004;36:2991-2992.
24. Sis B, Sarioglu S, Sokmen S, Sakar M, Kupelioglu A, Fuzun M. Desmoplasia measured by computer assisted image analysis: An independent prognostic marker in colorectal carcinoma. J Clin Pathol 2005;58:32-38.
25. Sokmen S, Lebe B, Sarioglu S, Fuzun M, Terzi C, Kupelioglu A, Ellidokuz H. Prognostic value of CD44 expression in colorectal carcinomas. Anticancer Res 2001;21:4121-4126.
26. Atar MA, Donn SM. Mechanisms of ventilator-induced lung injury in premature infants. Semin Neonatol 2002;7:353-360.
27. Pagano A, Barazzone-Argiroffo C. Alveolar cell death in hyperoxia-induced lung injury. Ann NY Acad Sci 2003;1010:405-416.
28. Dieperink HI, Blackwell TS, Prince LS. Hyperoxia and apoptosis in developing mouse lung mesenchyme. Pediatr Res 2006;59:185-190.
29. Sue RD, Belperio JA, Burdick MD, Murray LA, Xue YY, Dy MC, Kwon JJ, Keane MP, Strieter RM. CXCR2 is critical to hyperoxia-induced lung injury. J Immunol 2004;172:3860-3868.
30. Wagenaar GT, ter Horst SA, van Gastelen MA, Leijser LM, Mauad T, van der Velden A, de Heer E, Hiemstra PS, Poorthuis BJ, Walther FJ. Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. Free Radic Biol Med 2004;36:782-801.
31. Pinto LA, Camozzato C, Avozani M, Machado DC, Jones MH, Stein RT, Pitrez PM. Effect of clarithromycin on the cell profile of bronchoalveolar lavage fluid in mice with neutrophil-predominant lung disease. Rev Hosp Clin Fac Med Sao Paulo 2004;59:99-103.
32. Shinkai M, Rubin BK. Macrolides and airway inflammation in children. Paediatr Respir Rev 2005;6:227-235.
33. Gavino R, Johnson L, Bhandari V. Release of cytokines and apoptosis in fetal rat type II pneumocytes exposed to hyperoxia and nitric oxide: Modulatory effects of dexamethasone and pentoxifylline. Cytokine 2002;20:247-255.
34. Ladha F, Bonnet S, Eaton F, Hashimoto K, Korbutt G, Thébaud B. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am J Respir Crit Care Med 2005;172:750-756.
35. Yonemaru M, Hatherill JR, Hoffmann H, Zheng H, Ishil K, Raffin TA. Pentoxifylline does not attenuate acute lung injury in the absence of granulocytes. J Appl Physiol 1991;71:342-351.
36. Weinberger B, Laskin DL, Heck DE, Laskin JD. Oxygen toxicity in premature infants. Toxicol Appl Pharmacol 2002;181:60-67.